There are only two weeks to go until the 31 October deadline, don't miss it - get your entry in now!Highlighting this important area of work within the pharmaceutical industry, the new Medical & Scientific Excellence Awards are designed to recognise the outstanding achievements of medical and scientific professionals.
A pivotal Phase III trial investigating a combination of MSD’s anti-PD-1 therapy Keytruda and Pfizer’s tyrosine kinase inhibitor Inlyta has shown a significant benefit on both overall (OS) and progression-free survival (PFS) in patients with kidney cancer.
ViiV Healthcare has submitted a New Drug Application to the US Food and Drug Administration seeking permission to market a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV.
Health secretary Matt Hancock has unveiled his vision for technology in healthcare, which, he claims, will lay the foundation for a new generation of digital services able to meet the needs of clinicians, patients and managers.
The NHS now has three months to ensure that Novartis’ combination therapy dabrafenib/trametinib is routinely available to eligible skin cancer patients, after cost regulators published guidance backing funds for the treatment.
Samsung Bioepis has announced the European launch of Humira biosimilar Imraldi, as NHS chiefs tell Trusts to ensure they are ready to realise the potential savings from using cheaper versions of the world’s biggest selling drug.